Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs semaglutide, cagrilintide and placebo in CKD with type 2 diabetes and obesity
jRCT2031230700Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Modality
- Peptides
01
Overview
Randomised, double-blind trial of CagriSema in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), Overweight and 1 more (4 arms), sponsored by Novo Nordisk. Primary endpoint: Improvement in surrogate markers of CKD progression. Started Apr 2024; status: completed.
02
Drugs
CagriSema
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)Overweightobesity
Beyond the preview
Go deeper on jRCT2031230700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230700.